×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Featured Press Releases
Secretome Therapeutics' STM-01, a neonatal cardiac progenitor cell therapy for HFpEF, receives FDA Fast Track designation
FDA approves Bristol Myers Squibb's COBENFY™, a novel treatment for adult schizophrenia.
27 Sep 2024
Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has
...
Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341
The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter
New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday
Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.
Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure
By
Avantor and Financial News
Avantor and Financial News
14 Apr 2026
Recent Innovations Showcased by Baxter
By
Baxter International Inc.
Baxter International Inc.
13 Apr 2026
Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro
By
Ro
Ro
09 Apr 2026
Approval and Launch of Nintedanib Capsules
By
Dexcel Pharma USA
Dexcel Pharma USA
09 Apr 2026
When Every Beat Matters, BD Helps Clinicians Gain Continuous, Noninvasive Blood Pressure Insight to Eliminate Blind Spots
By
BD
BD
07 Apr 2026
Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences
By
Curve Biosciences
Curve Biosciences
07 Apr 2026
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
Zydus announces an exclusive licensing and supply agreement for two Gadolinium-based MRI injectable contrast agents in the U.S
By
Zydus Lifesciences Limited
Sep 16
Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research
By
AudioCure
Jul 07
BioMarin to Present Data Showcasing VOXZOGO® (vosoritide)'s Impact on Bone Health and Quality of Life in Achondroplasia
By
BioMarin Pharmaceutical Inc.
Jun 17
April
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe for e-Newsletter Monthly
Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
Email
I consent to subscribing to the selected email lists.
Enter the code below
Subscribe
1
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand
